The past 20 years have witnessed remarkable and unprecedented advances in the treatment of multiple sclerosis (MS), culminating in regulatory approval of 15 disease-modifying therapies (DMT) as of May 2017. The majority of these DMTs were initially developed based on the understanding that MS is an autoimmune disease, mounted by CD4+ T cells reactive against central nervous system (CNS) antigens. These T cells are, ostensibly, primed in peripheral lymphoid tissues and cross the blood-brain barrier to initiate inflammatory demyelination. The autoimmune hypothesis of MS is corroborated by the mechanisms of action of DMT that prevent new lesion formation and clinical relapses via the depletion of circulating lymphocytes or blockade of their trafficking to the CNS. Genome-wide association studies have substantiated a role of innate and adaptive immune pathways in determining susceptibility to MS. Nonetheless, relatively little is known about the mechanisms that underlie the activation, differentiation, and effector functions of encephalitogenic T cells. An expanding body of the literature has provided some clues through the identification of intrinsic and extrinsic factors that alter the risk and/or clinical characteristics of MS by triggering immune dysregulation, modulating interactions between inflammatory and CNS resident cells, or enhancing the vulnerability of neurons, axons, and glia to inflammatory insults and downstream neurodegenerative processes. The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2017 brought together a multidisciplinary team of basic and clinical researchers to discuss the impact of environmental, genetic, and epigenetic factors on MS susceptibility and clinical course. The series of articles in this special edition reflect the breadth and depth of the topics that were discussed.
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One theme that emerged from the Forum is that MS risk factors interact in intricate and sometimes unexpected ways. For example, single nucleotide polymorphisms (SNPs) that are in proximity to genes implicated in Vitamin D synthesis or metabolism, as well as SNPs associated with body mass index (BMI), independently alter the risk of MS. The interplay of these genetic variants with dietary and exercise habits, sun exposure, and other environmental factors reflect the complex, multifaceted etiology of MS. Furthermore, the effects of diet are closely linked to the microbiome. Studies in animal models indicate that consumption of large quantities of long-chain fatty acids (LCFA) alters the bacterial composition of the gut microbiome in a manner that favors the differentiation of encephalitogenic T cells and increases susceptibility to autoimmune demyelinating disease, whereas oral administration of short-chain fatty acids (SCFAs) triggers the expansion of bacterial species that support the differentiation of regulatory T cells and enhance disease resistance. Conversely, the composition of the microbiota can influence the course of MS by regulating the synthesis, digestion, and/or absorption of nutrients with immunomodulatory or neuroprotective properties, including SCFA, tryptophan metabolites, and biotin. Obesity in combination with an early age of sexual maturity has been associated with an earlier age of pediatric MS onset, suggesting a synergistic relationship between female hormones and metabolic pathways in escalating MS risk. Finally, evidence was provided that exposure to Epstein-Barr virus, an established MS risk factor, can activate human endogenous retroviruses that have also been implicated in MS disease activity.
Another theme emphasized during the Forum was that the clinical impact of genetic or environmental influences is context-dependent. Several speakers discussed the fact that a number of MS risk factors are sex-and/or age-specific. Hence, obesity in prepubescent females, but not males, correlates with a higher risk of developing MS in adulthood. However, low testosterone levels in utero may increase the future risk of MS in males. The relative contribution of a particular environmental factor to MS susceptibility may vary between geographic regions. For example, the protective effect of Vitamin D supplementation is amplified in individuals who live in locations with high annual sunlight exposure. A beneficial role of SCFAs in ameliorating MS is more likely to be realized among populations that consume fiber-rich diets, since SCFAs are produced consequent to fermentation of fiber in the colon. The cellular target of a given disease-modifying factor is also critical in determining its impact. Decreased histone acetylation and increased DNA methylation in oligodendrocyte lineage cells enhance myelin repair, while the same epigenetic modifications in T cells augment their pro-inflammatory phenotype. Sex hormones have pleiotropic, and sometime opposing, effects on different cell types, including leukocytes, microglia, oligodendrocytes, and neurons. The expression of certain X chromosome genes in T cells skews their differentiation toward a regulatory lineage, while X chromosome genes in neurons modulate susceptibility to inflammation-driven neurodegeneration.
In addition to providing a comprehensive review of the published literature on susceptibility and diseasemodifying factors in MS, and placing those factors into a broader conceptual framework, Forum speakers and poster presenters shared cutting edge discoveries in the field. A primary mission of ACTRIMS is to foster productive exchanges and innovative collaborations in MS research between investigators who represent diverse perspectives and areas of expertise. By all indications, the 2017 Forum achieved that goal. Future efforts to further decipher the networks of interactive genetic and environmental factors that regulate MS susceptibility and/or clinical course in different demographic cohorts will increase our understanding of the spectrum of cellular and molecular pathways that can drive MS pathogenesis. Such an approach is likely to help identify novel biomarkers, modifiable lifestyle behaviors, and therapeutic targets relevant to specific subpopulations of MS patients that will ultimately facilitate a more precise, customized approach to their treatment.
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